8.12-8.18 | 临床研究顶刊快报

文摘   教育   2024-08-19 10:08   中国香港  



References
1. Lu, S., et al., Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine, 2024. 391(7): p. 585-597.
2. Bodien, Y.G., et al., Cognitive Motor Dissociation in Disorders of Consciousness. New England Journal of Medicine, 2024. 391(7): p. 598-608.
3. Card, N.S., et al., An Accurate and Rapidly Calibrating Speech Neuroprosthesis. New England Journal of Medicine, 2024. 391(7): p. 609-618.
4. Vansteensel, M.J., et al., Longevity of a Brain–Computer Interface for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2024. 391(7): p. 619-626.
5. Devereux, G., et al., Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. JAMA, 2024. 332(6): p. 462-470.
6. Temel, J.S., et al., Stepped Palliative Care for Patients With Advanced Lung Cancer: A Randomized Clinical Trial. JAMA, 2024. 332(6): p. 471-481.
7. Barnard, M.E., et al., Endometriosis Typology and Ovarian Cancer Risk. JAMA, 2024. 332(6): p. 482-489.
8. Bels, J.L.M., et al., Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands. The Lancet, 2024. 404(10453): p. 659-669.
9. Rega, F., et al., Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. The Lancet, 2024. 404(10453): p. 670-682.
10. Taylor, L., et al., Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial. The Lancet, 2024. 404(10453): p. 683-691.

封面图片、部分文字参考新英格兰医学杂志和新英格兰医学前沿。

临沿weekly
最新鲜、最重磅又最简洁的临研报道和一些不太眼熟的统计学方法,每周更新,定期汇总,一起成为那个懂方法学的医生/懂临床前沿的方法学家。